Senior Leadership Team

Adam S. Grossman
Founder, Director, President & Chief Executive Officer

Mr. Grossman has been the driving force behind ADMA Biologics’ mission to develop and bring to market novel plasma derived products to address certain unmet medical needs for immune compromised patients.

He began his career as a hospital-based plasma products sales representative focusing on immune compromised patients. This opportunity provided him with a first-hand view of certain challenges patients faced while gaining an understanding of how some patients medical needs are handled by treating clinicians. Mr. Grossman has over 25 years of experience in the blood and plasma products industry which includes experience in launching new products, building and managing national and international sales forces as well as managing and designing clinical trials. Additionally, he has negotiated and completed numerous business development transactions. Under his leadership, Mr. Grossman brought ADMA public in 2013 and has completed over $300M in capital markets financing and debt transactions throughout his career.

Mr. Grossman led the asset acquisition of the Biotest Therapy Business Unit in 2017, which transformed ADMA Biologics into one of a handful of vertically integrated plasma products manufacturing companies based in the US. Subsequent to the asset acquisition, he is credited with leading the successful integration of business operations, revamping and overhauling the site-wide quality and compliance functions, and leading the regulatory affairs strategy resulting in FDA approvals for BIVIGAM®’s Prior Approval Supplement (PAS) and ASCENIV™’s BLA as well as the receipt of a new FDA license for the Boca Raton manufacturing plant.

Mr. Grossman has been a member of the ADMA Biologics Board of Directors since 2007, has served as its President and Chief Executive Officer since October 2011 and was the President and Chief Operating Officer between 2007 and October 2011. In 2016, he was issued several patents which are the basis for the manufacturing methods and composition for ASCENIV™. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, positions he held between 1994 and 2011. Previously, he worked at MedImmune, Inc. as part of the marketing team for RSV and CMV immunoglobulins and at the American Red Cross, where he participated in the launch of new products with the Biomedical Services division.

Mr. Grossman is a graduate of American University, receiving a B.S. in Business Administration, with a specialization in International Business and Marketing. Mr. Grossman is the son of Dr. Jerrold B. Grossman, ADMA's Vice-Chairman and co-founder. Mr. Grossman was chosen to serve on the Board because he has broad expertise in the plasma products industry and as the Company's Chief Executive Officer, he is able to provide the Board with critical insight into the day-to-day operations of the Company.

Brian Lenz, CPA
Executive Vice President, Chief Financial Officer

Mr. Lenz joined ADMA as Vice President, Chief Financial Officer in May 2012 and was instrumental in preparing the Company to go public and begin trading on the NASDAQ in October 2013. In June 2018, Mr. Lenz was promoted to Executive Vice President and Chief Financial Officer.  Mr. Lenz co-led the Biotest Therapy Business Unit (“BTBU”) acquisition team.  In this role, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction.

Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s financial reporting and SOX compliance activities amongst other operational duties.

Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.

Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.

Mr. Lenz is the finance committee co-chairperson for BioNJ.  He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.

Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include:  Best Growth Manager, Financier of the Year, Public Company and Capital Success.

James Mond, M.D., Ph.D.
Chief Scientific and Medical Officer

Dr. Mond joined ADMA as EVP, Chief Scientific and Medical Officer in July 2012 and leads the organization’s scientific, medical and R&D functions. During his tenure, Dr. Mond has designed and led clinical trials which formed the basis of clinical evidence to support the Company’s FDA approval for ASCENIV™ as well as led certain aspects of the Company’s acquisition of the Biotest Therapy Business unit. Dr. Mond was instrumental in overseeing the successful optimization of the BIVIGAM® and ASCENIV™ manufacturing process, and in securing the company’s intellectual property estate with his most recent patents being for a novel hyper immune globulin product targeted to 23 serotypes of s. Pneumoniae. Dr. Mond has authored over 170 publications in the fields of immunology, rheumatology, infectious diseases, vaccines and plasma products as well as multiple medical textbook chapters. He is credited with over 20 patents issued in the area of vaccines and immune globulins.

Prior to joining ADMA, Dr. Mond was Chief Scientific Officer and Executive Vice President at Biosynexus, where he was responsible for the preclinical and clinical development of three drug candidates from December 1999 through June 2011. Prior to this, he led the laboratory of Immunology and a practicing physician at the Uniformed Services University of the Health Sciences at the National Institute of Health (NIH) and was a professor of Medicine, Rheumatology and Immunology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Mond’s laboratory at the NIH invented a patented vaccine technology that was licensed to GlaxoSmithKline and is currently the basis of a number of pediatric vaccines that are commercialized globally.

Dr. Mond received his M.D. and Ph.D. from New York University School of Medicine.

Mr. Grossman has been the driving force behind ADMA Biologics’ mission to develop and bring to market novel plasma derived products to address certain unmet medical needs for immune compromised patients.

He began his career as a hospital-based plasma products sales representative focusing on immune compromised patients. This opportunity provided him with a first-hand view of certain challenges patients faced while gaining an understanding of how some patients medical needs are handled by treating clinicians. Mr. Grossman has over 25 years of experience in the blood and plasma products industry which includes experience in launching new products, building and managing national and international sales forces as well as managing and designing clinical trials. Additionally, he has negotiated and completed numerous business development transactions. Under his leadership, Mr. Grossman brought ADMA public in 2013 and has completed over $300M in capital markets financing and debt transactions throughout his career.

Mr. Grossman led the asset acquisition of the Biotest Therapy Business Unit in 2017, which transformed ADMA Biologics into one of a handful of vertically integrated plasma products manufacturing companies based in the US. Subsequent to the asset acquisition, he is credited with leading the successful integration of business operations, revamping and overhauling the site-wide quality and compliance functions, and leading the regulatory affairs strategy resulting in FDA approvals for BIVIGAM®’s Prior Approval Supplement (PAS) and ASCENIV™’s BLA as well as the receipt of a new FDA license for the Boca Raton manufacturing plant.

Mr. Grossman has been a member of the ADMA Biologics Board of Directors since 2007, has served as its President and Chief Executive Officer since October 2011 and was the President and Chief Operating Officer between 2007 and October 2011. In 2016, he was issued several patents which are the basis for the manufacturing methods and composition for ASCENIV™. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, positions he held between 1994 and 2011. Previously, he worked at MedImmune, Inc. as part of the marketing team for RSV and CMV immunoglobulins and at the American Red Cross, where he participated in the launch of new products with the Biomedical Services division.

Mr. Grossman is a graduate of American University, receiving a B.S. in Business Administration, with a specialization in International Business and Marketing. Mr. Grossman is the son of Dr. Jerrold B. Grossman, ADMA's Vice-Chairman and co-founder. Mr. Grossman was chosen to serve on the Board because he has broad expertise in the plasma products industry and as the Company's Chief Executive Officer, he is able to provide the Board with critical insight into the day-to-day operations of the Company.

Close

Mr. Lenz joined ADMA as Vice President, Chief Financial Officer in May 2012 and was instrumental in preparing the Company to go public and begin trading on the NASDAQ in October 2013. In June 2018, Mr. Lenz was promoted to Executive Vice President and Chief Financial Officer.  Mr. Lenz co-led the Biotest Therapy Business Unit (“BTBU”) acquisition team.  In this role, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction.

Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s financial reporting and SOX compliance activities amongst other operational duties.

Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.

Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.

Mr. Lenz is the finance committee co-chairperson for BioNJ.  He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.

Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include:  Best Growth Manager, Financier of the Year, Public Company and Capital Success.

Close

Dr. Mond joined ADMA as EVP, Chief Scientific and Medical Officer in July 2012 and leads the organization’s scientific, medical and R&D functions. During his tenure, Dr. Mond has designed and led clinical trials which formed the basis of clinical evidence to support the Company’s FDA approval for ASCENIV™ as well as led certain aspects of the Company’s acquisition of the Biotest Therapy Business unit. Dr. Mond was instrumental in overseeing the successful optimization of the BIVIGAM® and ASCENIV™ manufacturing process, and in securing the company’s intellectual property estate with his most recent patents being for a novel hyper immune globulin product targeted to 23 serotypes of s. Pneumoniae. Dr. Mond has authored over 170 publications in the fields of immunology, rheumatology, infectious diseases, vaccines and plasma products as well as multiple medical textbook chapters. He is credited with over 20 patents issued in the area of vaccines and immune globulins.

Prior to joining ADMA, Dr. Mond was Chief Scientific Officer and Executive Vice President at Biosynexus, where he was responsible for the preclinical and clinical development of three drug candidates from December 1999 through June 2011. Prior to this, he led the laboratory of Immunology and a practicing physician at the Uniformed Services University of the Health Sciences at the National Institute of Health (NIH) and was a professor of Medicine, Rheumatology and Immunology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Mond’s laboratory at the NIH invented a patented vaccine technology that was licensed to GlaxoSmithKline and is currently the basis of a number of pediatric vaccines that are commercialized globally.

Dr. Mond received his M.D. and Ph.D. from New York University School of Medicine.

Close
Neal C. Fitzpatrick
Vice President, Sales

Neal has a talent for building world-class sales teams and leading them to produce consistently stellar results.

In his prior role at Kedron Biopharma, he held the position of Vice President, Commercial Head for more than 8 years; January 2012 to September 2020 – launching the commercial organization in the United States. He was responsible for hiring and developing the North American commercial organization. The company’s areas of expertise include; Immunology/Neurology, Critical Care, Woman’s Health and Bleeding Disorders. Neal lead the launch or re-launch of 6 biologic products within those specialties. Neal’s success is centered on building a culture based on strong social responsibility. He models his teams around the obligation to the patients they serve, the colleagues they partner with and the communities in which they live.

Neal has spent more than 30 years successfully leading departments and organizations; honing his leadership skills at companies such as United Therapeutics, Novo Nordisk, Wyeth, Genetics Institute and Bristol-Myers Squibb. He has previously served as the Chairman of the Plasma Protein Therapeutics Association (PPTA) North American Advisory Board.

Neal received his Bachelor of Science degree in Pharmacy from the University of Rhode Island and continued his training at Wharton College with courses on strategic leadership, financial business management and team building.

Daniel Garcia
Vice President, IgG Product Management

Mr. Daniel Garcia is Vice President of IgG Product Management for ADMA Biologics and is responsible for management of IgG products, serving on strategic business and continuous improvement assignments.  

Mr. Garcia joined ADMA Biologics April of 2016 as the VP of Manufacturing and Technical Operations. Prior to joining ADMA he was Senior Production Manager at Baxter Healthcare, an integral team member developing a new IGIV product. As Senior Director of Operations and Technical Development at Emergent Biosolutions, Mr. Garcia was on the development team and later headed the manufacturing and process development functions in the production of anthrax vaccine (Biothrax), a commercial vaccine for the DOD in support of U.S. Military personnel. At Shanghai RAAS Blood Products, Mr. Garcia led a project as VP of Operations, constructing a 3 million liter automated blood fractionation plant in compliance with U.S. FDA, EMEA and ISO-9001 accreditation standards. Mr. Garcia served as COO at Biocell Laboratories where he was responsible for developing and commercializing numerous FDA approved clinical controls, calibrators and medical devices.  At Molecular GPS, as VP of Manufacturing, Mr. Garcia designed and constructed a cGMP modular cleanroom production facility to manufacture targeted small molecule anti-cancer therapeutics and vaccine.

With over 30 years of Pharmaceutical, Manufacturing, and Operations experience in production of FDA licensed small volume parenteral therapeutics, vaccines and medical devices, Mr. Garcia led development, manufacturing and engineering teams across numerous therapeutic areas. He holds a Bachelor degree from California State University Los Angeles and a Master of Science degree from California State University Northridge.

Kaitlin Kestenberg
Vice President, Compliance and Project Management

As Vice President of Compliance, Project Management and Clinical Operations for ADMA Biologics, Ms. Kestenberg is responsible for ensuring Company activities comply with regulations and the expectations of governing bodies as well as oversees company-wide project planning, project management and oversight for clinical programs and operations.

Along with the executive team, Kaitlin was instrumental in conducting due diligence on the Biotest Therapy Business Unit acquisition as well as playing an integral role in integration of corporate operations, compliance and FDA regulated functions. She led significant portions of ADMA’s compliance and quality assurance overhaul, worked on teams developing novel regulatory affairs strategies, led the team responsible for drafting the ASCENIV™ BLA and other significant regulatory submissions and is credited with preparing the company for a successful FDA inspection post acquisition. Ms. Kestenberg has participated in and led numerous FDA interactions for ADMA and has attended multiple face-to-face FDA meetings during her tenure.

Ms. Kestenberg joined ADMA Biologics as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Prior to joining ADMA, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics and Merck.

Ms. Kestenberg has over 12 years of project management and clinical operations experience including successful phase 3 clinical trials and subsequent regulatory filings. She was responsible for all operational aspects and site management and oversite of ADMA’s Phase III clinical program used as the basis for ADMA’s drug approval for ASCENIV™. She has led cross-functional teams across numerous therapeutic areas including immunology, infectious diseases, multiple sclerosis, congestive heart failure, acute spinal cord injury, HIV, hepatitis Clostridioides difficile, and diabetes.

She holds a bachelor’s degree from the State University of New York at Albany.

Michael Least
Vice President, Sales & Commercial Operations

As Vice President of Sales & Commercial Operations for ADMA Biologics, Mr. Least brings experience of more than 30 years in the healthcare industry with a focus on specialty product manufacturing, sales, distribution, and commercial operations. Previously as Vice President of Sales for ASD Healthcare, he helped to grow specialty distribution from $9B to over $15B in annual sales. Mr. Least has held various roles and responsibilities including: sales, sales leadership, marketing, medical affairs, training, account management, business development and executive leadership. He has worked for large premier manufacturers and distributors (Searle, Pfizer, Eisai, Johnson & Johnson, AmerisourceBergen), as well as entrepreneurial biotech companies. His extensive knowledge and expertise has resulted in consistent success, with a unique perspective of the U.S. specialty care market and the challenges facing manufacturers, distributors, healthcare providers, health systems and academic medical centers of excellence.

Neal has a talent for building world-class sales teams and leading them to produce consistently stellar results.

In his prior role at Kedron Biopharma, he held the position of Vice President, Commercial Head for more than 8 years; January 2012 to September 2020 – launching the commercial organization in the United States. He was responsible for hiring and developing the North American commercial organization. The company’s areas of expertise include; Immunology/Neurology, Critical Care, Woman’s Health and Bleeding Disorders. Neal lead the launch or re-launch of 6 biologic products within those specialties. Neal’s success is centered on building a culture based on strong social responsibility. He models his teams around the obligation to the patients they serve, the colleagues they partner with and the communities in which they live.

Neal has spent more than 30 years successfully leading departments and organizations; honing his leadership skills at companies such as United Therapeutics, Novo Nordisk, Wyeth, Genetics Institute and Bristol-Myers Squibb. He has previously served as the Chairman of the Plasma Protein Therapeutics Association (PPTA) North American Advisory Board.

Neal received his Bachelor of Science degree in Pharmacy from the University of Rhode Island and continued his training at Wharton College with courses on strategic leadership, financial business management and team building.

Close

Mr. Daniel Garcia is Vice President of IgG Product Management for ADMA Biologics and is responsible for management of IgG products, serving on strategic business and continuous improvement assignments.  

Mr. Garcia joined ADMA Biologics April of 2016 as the VP of Manufacturing and Technical Operations. Prior to joining ADMA he was Senior Production Manager at Baxter Healthcare, an integral team member developing a new IGIV product. As Senior Director of Operations and Technical Development at Emergent Biosolutions, Mr. Garcia was on the development team and later headed the manufacturing and process development functions in the production of anthrax vaccine (Biothrax), a commercial vaccine for the DOD in support of U.S. Military personnel. At Shanghai RAAS Blood Products, Mr. Garcia led a project as VP of Operations, constructing a 3 million liter automated blood fractionation plant in compliance with U.S. FDA, EMEA and ISO-9001 accreditation standards. Mr. Garcia served as COO at Biocell Laboratories where he was responsible for developing and commercializing numerous FDA approved clinical controls, calibrators and medical devices.  At Molecular GPS, as VP of Manufacturing, Mr. Garcia designed and constructed a cGMP modular cleanroom production facility to manufacture targeted small molecule anti-cancer therapeutics and vaccine.

With over 30 years of Pharmaceutical, Manufacturing, and Operations experience in production of FDA licensed small volume parenteral therapeutics, vaccines and medical devices, Mr. Garcia led development, manufacturing and engineering teams across numerous therapeutic areas. He holds a Bachelor degree from California State University Los Angeles and a Master of Science degree from California State University Northridge.

Close

As Vice President of Compliance, Project Management and Clinical Operations for ADMA Biologics, Ms. Kestenberg is responsible for ensuring Company activities comply with regulations and the expectations of governing bodies as well as oversees company-wide project planning, project management and oversight for clinical programs and operations.

Along with the executive team, Kaitlin was instrumental in conducting due diligence on the Biotest Therapy Business Unit acquisition as well as playing an integral role in integration of corporate operations, compliance and FDA regulated functions. She led significant portions of ADMA’s compliance and quality assurance overhaul, worked on teams developing novel regulatory affairs strategies, led the team responsible for drafting the ASCENIV™ BLA and other significant regulatory submissions and is credited with preparing the company for a successful FDA inspection post acquisition. Ms. Kestenberg has participated in and led numerous FDA interactions for ADMA and has attended multiple face-to-face FDA meetings during her tenure.

Ms. Kestenberg joined ADMA Biologics as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Prior to joining ADMA, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics and Merck.

Ms. Kestenberg has over 12 years of project management and clinical operations experience including successful phase 3 clinical trials and subsequent regulatory filings. She was responsible for all operational aspects and site management and oversite of ADMA’s Phase III clinical program used as the basis for ADMA’s drug approval for ASCENIV™. She has led cross-functional teams across numerous therapeutic areas including immunology, infectious diseases, multiple sclerosis, congestive heart failure, acute spinal cord injury, HIV, hepatitis Clostridioides difficile, and diabetes.

She holds a bachelor’s degree from the State University of New York at Albany.

Close

As Vice President of Sales & Commercial Operations for ADMA Biologics, Mr. Least brings experience of more than 30 years in the healthcare industry with a focus on specialty product manufacturing, sales, distribution, and commercial operations. Previously as Vice President of Sales for ASD Healthcare, he helped to grow specialty distribution from $9B to over $15B in annual sales. Mr. Least has held various roles and responsibilities including: sales, sales leadership, marketing, medical affairs, training, account management, business development and executive leadership. He has worked for large premier manufacturers and distributors (Searle, Pfizer, Eisai, Johnson & Johnson, AmerisourceBergen), as well as entrepreneurial biotech companies. His extensive knowledge and expertise has resulted in consistent success, with a unique perspective of the U.S. specialty care market and the challenges facing manufacturers, distributors, healthcare providers, health systems and academic medical centers of excellence.

Close
Drew Pantello
Vice President, Marketing & Corporate Development

Mr. Pantello is Vice President of Marketing and Corporate Development for ADMA Biologics. He is responsible for leading marketing and business development efforts across all the ADMA immunoglobulin brands.

Prior to joining ADMA Biologics in January of 2018, Mr. Pantello was the account management lead supporting ADMA’s launch preparation activities at H4B Chelsea/Havas Health. At H4B/Havas, he worked hand in hand with the executive team at ADMA Biologics for more than 4 years dissecting the layers of the plasma products market, leading all market research and focus group activities to gain insights and form the basis for the company’s marketing strategies. Drew brings to ADMA the experience of holding various roles of increasing responsibility and working on product launches across a wide range of therapeutic categories for more 20+ years in pharmaceutical market research, advertising and marketing. He has held positions at LM&P, Euro RSCG Life, H4B Chelsea and Havas Health across Account Management and Business Development functions. He was responsible for leading numerous major product launches for brands across immunology, HIV, infectious disease, diabetes and neuroscience.

Mr. Pantello holds a bachelor’s degree in History from Ramapo College of New Jersey.

Adam Pinkert
Vice President, Quality and Regulatory Affairs

Mr. Pinkert is the Vice President of Quality and Regulatory Affairs for ADMA Biologics. In this Position, he is responsible for quality and regulatory compliance across all GMP activities for the Company. Mr. Pinkert led significant portions of ADMA’s quality assurance overhaul and was on the leadership team to implement the Compliance Enhancement Plan post the acquisition of the Biotest Therapy Business Unit by ADMA. He worked on and led teams responsible for drafting revised quality assurance and quality control procedures to bring the manufacturing site up to current FDA expectations, provided oversight to multiple regulatory affairs submissions and is credited with preparing the company for a successful FDA inspection post acquisition.

Mr. Pinkert formally joined ADMA Biologics as Vice President of Quality in August 2017 after serving as a consultant to ADMA prior to its acquisition. Prior to this, he held various leadership positions including Site Head of Quality and Head of Quality Engineering and Validation at Genentech/Roche. He also served in roles of increasing responsibility at Bayer Biologics in Manufacturing and Process Development.

Mr. Pinkert has more than 25 years of pharmaceutical and biologics experience, including compliance remediation, plasma production, antibody-drug conjugates, drug product and drug substance manufacturing, and validation. His experience includes a number of new drug and facility launches.

Mr. Pinkert is an ASQ Certified Six Sigma Black Belt. He holds a bachelor’s degree in Chemistry and Anthropology from the University of California at Berkeley and a Master of Engineering from Arizona State University.

Michael Space
Vice President, Supply Chain & Facility Management

Mr. Space is the Vice President of Supply Chain and Facility Operations.

He joined ADMA Biologics in September 2018. Prior to this, he worked for Hoffman-La Roche, holding leadership positions in process development, engineering, production, supply chain, finance, IT, and site management. With Roche, he worked on at several sites across the United States and internationally.

Mr. Space has more than 30 years of varied operational experience in the pharmaceutical industry. He led significant capital projects including the design and construction of a $50 million Vitamin plant and a $350 million Greenfield active pharmaceutical ingredient facility. He led a supply chain expansion program for an antiviral targeted at the prevention and treatment of a threatened global influenza pandemic.

Mr. Space holds a master’s in Business Administration from Rutgers University and a bachelor’s degree in Chemical Engineering from the University of Delaware.

Cyndi Tolman
Vice President, Plasma Services, ADMA BioCenters

Mrs. Tolman is Vice President of Plasma Services for ADMA Biologics and is responsible for ADMA Bio Centers. Mrs. Tolman joined ADMA Biologics in January 2008. She previously held a position as VP of Regulatory Affairs and Contract Manufacturing at GeoVax, Inc. Prior to joining GeoVax, she held various leadership positions at Serologicals, Inc. where she was eventually promoted to Managing Director.

Mrs. Tolman has more than 20 years of experience in the plasma industry. She is a registered licensed Medical Technologist with the American Society of Pathology (ASCP). She holds a bachelor’s degree in Medical Technology from the University of Tennessee and a master’s degree in Healthcare Administration from the Medical University of
South Carolina.

Mr. Pantello is Vice President of Marketing and Corporate Development for ADMA Biologics. He is responsible for leading marketing and business development efforts across all the ADMA immunoglobulin brands.

Prior to joining ADMA Biologics in January of 2018, Mr. Pantello was the account management lead supporting ADMA’s launch preparation activities at H4B Chelsea/Havas Health. At H4B/Havas, he worked hand in hand with the executive team at ADMA Biologics for more than 4 years dissecting the layers of the plasma products market, leading all market research and focus group activities to gain insights and form the basis for the company’s marketing strategies. Drew brings to ADMA the experience of holding various roles of increasing responsibility and working on product launches across a wide range of therapeutic categories for more 20+ years in pharmaceutical market research, advertising and marketing. He has held positions at LM&P, Euro RSCG Life, H4B Chelsea and Havas Health across Account Management and Business Development functions. He was responsible for leading numerous major product launches for brands across immunology, HIV, infectious disease, diabetes and neuroscience.

Mr. Pantello holds a bachelor’s degree in History from Ramapo College of New Jersey.

Close

Mr. Pinkert is the Vice President of Quality and Regulatory Affairs for ADMA Biologics. In this Position, he is responsible for quality and regulatory compliance across all GMP activities for the Company. Mr. Pinkert led significant portions of ADMA’s quality assurance overhaul and was on the leadership team to implement the Compliance Enhancement Plan post the acquisition of the Biotest Therapy Business Unit by ADMA. He worked on and led teams responsible for drafting revised quality assurance and quality control procedures to bring the manufacturing site up to current FDA expectations, provided oversight to multiple regulatory affairs submissions and is credited with preparing the company for a successful FDA inspection post acquisition.

Mr. Pinkert formally joined ADMA Biologics as Vice President of Quality in August 2017 after serving as a consultant to ADMA prior to its acquisition. Prior to this, he held various leadership positions including Site Head of Quality and Head of Quality Engineering and Validation at Genentech/Roche. He also served in roles of increasing responsibility at Bayer Biologics in Manufacturing and Process Development.

Mr. Pinkert has more than 25 years of pharmaceutical and biologics experience, including compliance remediation, plasma production, antibody-drug conjugates, drug product and drug substance manufacturing, and validation. His experience includes a number of new drug and facility launches.

Mr. Pinkert is an ASQ Certified Six Sigma Black Belt. He holds a bachelor’s degree in Chemistry and Anthropology from the University of California at Berkeley and a Master of Engineering from Arizona State University.

Close

Mr. Space is the Vice President of Supply Chain and Facility Operations.

He joined ADMA Biologics in September 2018. Prior to this, he worked for Hoffman-La Roche, holding leadership positions in process development, engineering, production, supply chain, finance, IT, and site management. With Roche, he worked on at several sites across the United States and internationally.

Mr. Space has more than 30 years of varied operational experience in the pharmaceutical industry. He led significant capital projects including the design and construction of a $50 million Vitamin plant and a $350 million Greenfield active pharmaceutical ingredient facility. He led a supply chain expansion program for an antiviral targeted at the prevention and treatment of a threatened global influenza pandemic.

Mr. Space holds a master’s in Business Administration from Rutgers University and a bachelor’s degree in Chemical Engineering from the University of Delaware.

Close

Mrs. Tolman is Vice President of Plasma Services for ADMA Biologics and is responsible for ADMA Bio Centers. Mrs. Tolman joined ADMA Biologics in January 2008. She previously held a position as VP of Regulatory Affairs and Contract Manufacturing at GeoVax, Inc. Prior to joining GeoVax, she held various leadership positions at Serologicals, Inc. where she was eventually promoted to Managing Director.

Mrs. Tolman has more than 20 years of experience in the plasma industry. She is a registered licensed Medical Technologist with the American Society of Pathology (ASCP). She holds a bachelor’s degree in Medical Technology from the University of Tennessee and a master’s degree in Healthcare Administration from the Medical University of
South Carolina.

Close
Kim Tripodo
Executive Director & Head of Human Resources and Administrative Operations

Ms. Tripodo is Executive Director & Head of Human Resources and Administrative Operations.  She has over 25 years of experience as a Human Resources professional and has held various positions of increasing responsibility in the pharmaceutical, health care and service industries. Ms. Tripodo has partnered with executive leadership teams to create business impact in financial, operational, sales, marketing, legal and technological strategy implementations.  Her last position was with TissueTech, Inc. as the Vice President of Human Resources where she focused on talent acquisition, talent development and organizational structure.

Ms. Tripodo has a Bachelor’s degree in Business Administration from Pace University in New York and a Master’s degree in Human Resources Education from Fordham University in New York.

Gene A. Wetzstein, PharmD, BCOP
Executive Director & Head of Scientific Engagement

Dr. Wetzstein is the Executive Director & Head of Scientific Engagement for ADMA Biologics.  In this role, he is responsible to ensure effective and collaborative medical relationships and scientific interchange with ADMA Biologics key medical healthcare partners.  

Gene has a diverse and accomplished career spanning over 20+ years in the academic and institutional practice setting. He earned his BS Pharmaceutical Sciences/ Chemistry and Doctorate of Pharmacy from North Dakota State University.    He then completed a Pharmacy Practice Residency at the University of Utah Hospitals and Clinics and an Oncology/ Hematology/ HSCT Specialty Residency at Moffitt Cancer Center & Research Institute.   He has been Board Certified in Oncology Pharmacy (BCOP) since 2000 and a licensed consultant (FL) pharmacist since 2010.   

Following his specialty residency training, Gene accepted a clinical specialist role in Malignant Hematology / Infectious Disease at Moffitt Cancer Center. Over his 18+ years, he held progressive leadership roles both within the clinical/ research and administrative settings, heading up Clinical Services/ Supportive Care Research and later Chief Pharmacy Officer overseeing the entire pharmacy enterprise. Gene has held multiple national leadership roles including Chair, Pharmacy Leadership Committee of the Alliance of Dedicated Cancers (ADCC).   He has also served on the Board of Directors of the Florida Society of Clinical Oncology (FLASCO).   Gene is recognized throughout the county as a true pharmacy thought leader and has been invited on multiple occasions to speak on oncology/ hematology/ supportive care related topics.   

Prior to joining ADMA Biologics, Gene was at TESARO/ GSK for the last 3 years in customer facing medical roles.    He worked closely with Institutional/ Practice key decision makers in alleviating any potential obstacles or challenges that may arise with the integration of a new product into their Systems/ Formularies.  As Head, US Field Value worked closely with internal partners to develop/ expand clinical data sets, refine, package, and deliver these critical product messages to key institutions/ practices/ centers of excellence.

Vernon Atkinson
Senior Director, ADMA BioCenters

Mr. Atkinson is the Sr. Director of Operations and has responsibility for the oversight of donor center operational activities.

He joined ADMA Biologics in November 2008 and prior held leadership positions at the American Red Cross and Serologicals. Mr. Atkinson has over 20 years of experience in the Biologics Industry which includes center development, project planning, team building, budget development, compliance activities, and operational improvement initiatives.

Mr. Atkinson received a BS in Business Administration from the University of Maryland.

Ricardo Carneiro
Senior Director, Market Access and Reimbursement

Mr. Carneiro brings nearly 20 years of Pharmaceutical and Biotechnology experience to ADMA Biologics, beginning his career at Pfizer Pharmaceuticals. Mr. Carneiro was part of a team that launched the newly acquired Anti Infective, Anti-Fungal and Pain Management portfolio to Healthcare Systems and providers as well as alternate sites of care.  He has worked across several therapeutic areas, such as Infectious Disease, Immunology, Neurology and Pain Management, as well as having extensive experience in sales, analytics, marketing, distribution and business development.

Mr. Carneiro’s focus over the past 10 years has been in Market Access and Reimbursement. He was recruited to build out the Market Access function at The Medicines Company, from Cubist Pharmaceuticals and was accountable for developing account specific value-based strategies.  He led a multidisciplinary field-based Market Access team, which was responsible for expanding access for the company’s newly launched portfolio in Nationally and Regionally based Healthcare Systems, Medicare, Medicaid, Commercial Payors, as well as alternate sites of care.  Mr. Carneiro then turned his focus on developing new nationally and regionally based cooperative and specialty pharmacy networks to support the launch of a new oral anti-infective after The Medicines Company Infectious disease franchise was acquired by Melinta Therapeutics.

Mr. Carneiro holds a Bachelor of Science degree in Finance and Economics from Montclair State University and is an active member of the American College of Healthcare Executives (ACHE).

Ms. Tripodo is Executive Director & Head of Human Resources and Administrative Operations.  She has over 25 years of experience as a Human Resources professional and has held various positions of increasing responsibility in the pharmaceutical, health care and service industries. Ms. Tripodo has partnered with executive leadership teams to create business impact in financial, operational, sales, marketing, legal and technological strategy implementations.  Her last position was with TissueTech, Inc. as the Vice President of Human Resources where she focused on talent acquisition, talent development and organizational structure.

Ms. Tripodo has a Bachelor’s degree in Business Administration from Pace University in New York and a Master’s degree in Human Resources Education from Fordham University in New York.

Close

Dr. Wetzstein is the Executive Director & Head of Scientific Engagement for ADMA Biologics.  In this role, he is responsible to ensure effective and collaborative medical relationships and scientific interchange with ADMA Biologics key medical healthcare partners.  

Gene has a diverse and accomplished career spanning over 20+ years in the academic and institutional practice setting. He earned his BS Pharmaceutical Sciences/ Chemistry and Doctorate of Pharmacy from North Dakota State University.    He then completed a Pharmacy Practice Residency at the University of Utah Hospitals and Clinics and an Oncology/ Hematology/ HSCT Specialty Residency at Moffitt Cancer Center & Research Institute.   He has been Board Certified in Oncology Pharmacy (BCOP) since 2000 and a licensed consultant (FL) pharmacist since 2010.   

Following his specialty residency training, Gene accepted a clinical specialist role in Malignant Hematology / Infectious Disease at Moffitt Cancer Center. Over his 18+ years, he held progressive leadership roles both within the clinical/ research and administrative settings, heading up Clinical Services/ Supportive Care Research and later Chief Pharmacy Officer overseeing the entire pharmacy enterprise. Gene has held multiple national leadership roles including Chair, Pharmacy Leadership Committee of the Alliance of Dedicated Cancers (ADCC).   He has also served on the Board of Directors of the Florida Society of Clinical Oncology (FLASCO).   Gene is recognized throughout the county as a true pharmacy thought leader and has been invited on multiple occasions to speak on oncology/ hematology/ supportive care related topics.   

Prior to joining ADMA Biologics, Gene was at TESARO/ GSK for the last 3 years in customer facing medical roles.    He worked closely with Institutional/ Practice key decision makers in alleviating any potential obstacles or challenges that may arise with the integration of a new product into their Systems/ Formularies.  As Head, US Field Value worked closely with internal partners to develop/ expand clinical data sets, refine, package, and deliver these critical product messages to key institutions/ practices/ centers of excellence.

Close

Mr. Atkinson is the Sr. Director of Operations and has responsibility for the oversight of donor center operational activities.

He joined ADMA Biologics in November 2008 and prior held leadership positions at the American Red Cross and Serologicals. Mr. Atkinson has over 20 years of experience in the Biologics Industry which includes center development, project planning, team building, budget development, compliance activities, and operational improvement initiatives.

Mr. Atkinson received a BS in Business Administration from the University of Maryland.

Close

Mr. Carneiro brings nearly 20 years of Pharmaceutical and Biotechnology experience to ADMA Biologics, beginning his career at Pfizer Pharmaceuticals. Mr. Carneiro was part of a team that launched the newly acquired Anti Infective, Anti-Fungal and Pain Management portfolio to Healthcare Systems and providers as well as alternate sites of care.  He has worked across several therapeutic areas, such as Infectious Disease, Immunology, Neurology and Pain Management, as well as having extensive experience in sales, analytics, marketing, distribution and business development.

Mr. Carneiro’s focus over the past 10 years has been in Market Access and Reimbursement. He was recruited to build out the Market Access function at The Medicines Company, from Cubist Pharmaceuticals and was accountable for developing account specific value-based strategies.  He led a multidisciplinary field-based Market Access team, which was responsible for expanding access for the company’s newly launched portfolio in Nationally and Regionally based Healthcare Systems, Medicare, Medicaid, Commercial Payors, as well as alternate sites of care.  Mr. Carneiro then turned his focus on developing new nationally and regionally based cooperative and specialty pharmacy networks to support the launch of a new oral anti-infective after The Medicines Company Infectious disease franchise was acquired by Melinta Therapeutics.

Mr. Carneiro holds a Bachelor of Science degree in Finance and Economics from Montclair State University and is an active member of the American College of Healthcare Executives (ACHE).

Close
Lucy DeMario, PhD
Senior Director, Analytical & Process Development

Dr. DeMario is the Senior Director Analytical and Process Development for ADMA Biologics. In this position she is responsible for managing the scientific operations’ discovery and development projects as they relate to the achieving of ADMA’s stated goals.

Dr. DeMario joined ADMA Biologics in 2008 as Director of Quality Systems. In 2017 she moved to Senior Director of ADMA Quality Control Laboratory at the Boca Raton facility before joining Scientific Operations into her current role in 2019.   Previously she held management positions in Quality Control, Manufacturing and Donor Screening at Inhibitex and Immucor. Dr. DeMario has more than 25 years of Quality and Laboratory experience including manufacturing oversight, laboratory management and preparation of regulatory submissions. She has managed teams across numerous plasma protein diagnostic and therapeutic areas for transfusion medicine, and infectious and rare diseases.

She holds a bachelor’s degree from Pfeiffer University, a doctorate from the University of Maryland and performed her post-doctoral studies at the National Cancer Institute.

Marc Gelberg
Senior Director, Corporate Controller

Mr. Gelberg is the Corporate Controller for ADMA Biologics. Mr. Gelberg is responsible for the financial reporting and accounting operations of ADMA, including preparation of the Company’s consolidated financial statements, SEC reporting, financial planning, and maintaining internal control over financial reporting under the Sarbanes-Oxley Act of 2002.

Mr. Gelberg joined ADMA Biologics in June 2017. Prior to joining ADMA, he held various financial leadership positions at both publicly traded and private companies, including: VeriTeQ Corporation, Fusion Telecommunications, and Cross Match Technologies. He has also worked as an independent consultant advising numerous clients in matters of technical accounting and SEC compliance. Mr. Gelberg began his career in the finance department within the parent corporation of Wyeth, Inc., a global biopharmaceutical company, where he held roles of increasing responsibility for 7 years.

He holds a bachelors’ degree in Economics from the State University of New York at Albany and is a Certified Public Accountant.

Jeffrey Gruenglas, DHSc(c) MBE, MA
Senior Director, Government Affairs and Health Policy

Mr. Gruenglas is Senior Director, Government Affairs and Health Policy, for ADMA Biologics. In this capacity, he plays a central role in developing and implementing coordinated advocacy strategies and engagements with governmental and policy entities around issues that impact the IVIG therapeutic area and biopharmaceuticals in general. Mr. Gruenglas serves under the office of the Chief Medical Officer and collaborates on developing policy and biomedical ethics research. Prior to this, Mr. Gruenglas was Managing Partner at New England Research Group (NERG), a life sciences research and analytics consultancy in the Greater Boston area, where he advised pharmaceutical and biotech organizations on research, commercialization, health policy, and regulatory affairs. Before this, he founded and served as Executive Vice President for the oncology business unit at a private-equity held life sciences consulting and communications firm. 

Mr. Gruenglas has lectured, published, and presented at national conferences and academic institutions in the areas of bioethics, management/organizational ethics, market access, and health policy. He is currently a faculty member at the College of Arts & Sciences, Boston University. Mr. Gruenglas holds degrees in medical ethics from Harvard Medical School and English literature and theory from City University of New York-Brooklyn College. He is a doctoral candidate in global health sciences at MCPHS University, and is certified in Data Analytics from Harvard Business School. Mr. Gruenglas is an EMT provider licensed in Massachusetts and New York, and he continues to teach and volunteer in this capacity. He is certified as an AHA instructor and in FEMA ICS and NIMS emergency planning.

Sheri Klostermeyer
Senior Director, Supply Chain Operations

Ms. Klostermeyer is the Senior Director of Supply Chain Operations for ADMA Biologics. She is responsible for logistics, inventory control, distribution of finished goods and production scheduling. She develops strategic plans and processes to improve productivity, quality, and efficiency of operations.

Ms. Klostermeyer has over 20 years’ experience in the biologics industry. She has held management positions with increasing responsibility at the ADMA Biologics manufacturing site across, Supply Chain, Accounting and Information Technology.

Ms. Klostermeyer holds a bachelor’s degree in operations management from Florida Atlantic University in Boca Raton, Florida.

Dr. DeMario is the Senior Director Analytical and Process Development for ADMA Biologics. In this position she is responsible for managing the scientific operations’ discovery and development projects as they relate to the achieving of ADMA’s stated goals.

Dr. DeMario joined ADMA Biologics in 2008 as Director of Quality Systems. In 2017 she moved to Senior Director of ADMA Quality Control Laboratory at the Boca Raton facility before joining Scientific Operations into her current role in 2019.   Previously she held management positions in Quality Control, Manufacturing and Donor Screening at Inhibitex and Immucor. Dr. DeMario has more than 25 years of Quality and Laboratory experience including manufacturing oversight, laboratory management and preparation of regulatory submissions. She has managed teams across numerous plasma protein diagnostic and therapeutic areas for transfusion medicine, and infectious and rare diseases.

She holds a bachelor’s degree from Pfeiffer University, a doctorate from the University of Maryland and performed her post-doctoral studies at the National Cancer Institute.

Close

Mr. Gelberg is the Corporate Controller for ADMA Biologics. Mr. Gelberg is responsible for the financial reporting and accounting operations of ADMA, including preparation of the Company’s consolidated financial statements, SEC reporting, financial planning, and maintaining internal control over financial reporting under the Sarbanes-Oxley Act of 2002.

Mr. Gelberg joined ADMA Biologics in June 2017. Prior to joining ADMA, he held various financial leadership positions at both publicly traded and private companies, including: VeriTeQ Corporation, Fusion Telecommunications, and Cross Match Technologies. He has also worked as an independent consultant advising numerous clients in matters of technical accounting and SEC compliance. Mr. Gelberg began his career in the finance department within the parent corporation of Wyeth, Inc., a global biopharmaceutical company, where he held roles of increasing responsibility for 7 years.

He holds a bachelors’ degree in Economics from the State University of New York at Albany and is a Certified Public Accountant.

Close

Mr. Gruenglas is Senior Director, Government Affairs and Health Policy, for ADMA Biologics. In this capacity, he plays a central role in developing and implementing coordinated advocacy strategies and engagements with governmental and policy entities around issues that impact the IVIG therapeutic area and biopharmaceuticals in general. Mr. Gruenglas serves under the office of the Chief Medical Officer and collaborates on developing policy and biomedical ethics research. Prior to this, Mr. Gruenglas was Managing Partner at New England Research Group (NERG), a life sciences research and analytics consultancy in the Greater Boston area, where he advised pharmaceutical and biotech organizations on research, commercialization, health policy, and regulatory affairs. Before this, he founded and served as Executive Vice President for the oncology business unit at a private-equity held life sciences consulting and communications firm. 

Mr. Gruenglas has lectured, published, and presented at national conferences and academic institutions in the areas of bioethics, management/organizational ethics, market access, and health policy. He is currently a faculty member at the College of Arts & Sciences, Boston University. Mr. Gruenglas holds degrees in medical ethics from Harvard Medical School and English literature and theory from City University of New York-Brooklyn College. He is a doctoral candidate in global health sciences at MCPHS University, and is certified in Data Analytics from Harvard Business School. Mr. Gruenglas is an EMT provider licensed in Massachusetts and New York, and he continues to teach and volunteer in this capacity. He is certified as an AHA instructor and in FEMA ICS and NIMS emergency planning.

Close

Ms. Klostermeyer is the Senior Director of Supply Chain Operations for ADMA Biologics. She is responsible for logistics, inventory control, distribution of finished goods and production scheduling. She develops strategic plans and processes to improve productivity, quality, and efficiency of operations.

Ms. Klostermeyer has over 20 years’ experience in the biologics industry. She has held management positions with increasing responsibility at the ADMA Biologics manufacturing site across, Supply Chain, Accounting and Information Technology.

Ms. Klostermeyer holds a bachelor’s degree in operations management from Florida Atlantic University in Boca Raton, Florida.

Close
James Maloney
Senior Director, Regulatory Affairs

Mr. Maloney is the Senior Director of Regulatory Affairs for ADMA Biologics. He is responsible for overseeing the development, planning, and implementation of ADMA Regulatory Affairs’ strategic mission as well as ensuring compliance with governmental regulations.

Mr. Maloney joined ADMA Biologics as Senior Director of Regulatory Affairs in September 2017. He worked on the team responsible for all of ADMA’s regulatory interactions post acquisition of the Biotest Therapy Business Unit including the submission of a Prior Approval Supplement for BIVIGAM®, Biologics License Application for ASCENIV™, responses to FDA inspectional observations as well as responding to standard information requests and day to day regulatory interactions and submissions.

Previously, he was as Associate Program Director of Regulatory Affairs at Genentech and was responsible for all US regulatory activities for multiple product lines. Prior to joining Genentech, he held roles of increasing responsibility at several major pharmaceutical companies including Roche, Barr Laboratories, Mylan, and Merck & Company.

Mr. Maloney has more than 20 years of experience in pharmaceuticals and biologics regulatory affairs. His experience spans numerous therapeutic areas including immunology, oncology, endocrinology, dermatology, neurology, and infectious diseases as well as rare diseases.

He holds a bachelor’s degree in Chemistry from Allegheny College.

Frank Sananes
Senior Director, Manufacturing & Validation

Mr. Sananes is the Senior Director of Manufacturing and Validation for ADMA Biologics. In this position, he is responsible for manufacturing and validation operations.

Mr. Sananes has been at the ADMA Biologics manufacturing site since 1998 in various positions including Manufacturing, Validation, and Process Development.

He has more than 30 years of pharmaceutical experience in plasma and vaccine production. Prior to joining ADMA, Mr. Sananes had roles of increasing responsibility at Roche and Wyeth in both Manufacturing and Quality Control.

Mr. Sananes holds bachelor’s and master’s degrees in Biology and Biochemistry from Rutgers University.

Skyler Bloom
Director, Investor Relations and Corporate Strategy

Mr. Bloom is the Director of Investor Relations and Corporate Strategy for ADMA Biologics. He serves as a strategic advisor to the senior management team for investor relations and business development opportunities as well as developing messaging for internal and external communications.

Mr. Bloom joined ADMA Biologics in August 2020. Prior to joining ADMA, he held analyst roles at multiple hedge funds including Sphera Global Healthcare and B Group Capital. In his former capacity, Mr. Bloom invested in both private and publicly traded healthcare companies. During his tenure at Sphera, Mr. Bloom played an integral role in growing the investment platform from $500 million assets under management to $1.8 billion at the time of his exit.

He earned his BA in Finance and Accounting from Southern Methodist University.

Mr. Maloney is the Senior Director of Regulatory Affairs for ADMA Biologics. He is responsible for overseeing the development, planning, and implementation of ADMA Regulatory Affairs’ strategic mission as well as ensuring compliance with governmental regulations.

Mr. Maloney joined ADMA Biologics as Senior Director of Regulatory Affairs in September 2017. He worked on the team responsible for all of ADMA’s regulatory interactions post acquisition of the Biotest Therapy Business Unit including the submission of a Prior Approval Supplement for BIVIGAM®, Biologics License Application for ASCENIV™, responses to FDA inspectional observations as well as responding to standard information requests and day to day regulatory interactions and submissions.

Previously, he was as Associate Program Director of Regulatory Affairs at Genentech and was responsible for all US regulatory activities for multiple product lines. Prior to joining Genentech, he held roles of increasing responsibility at several major pharmaceutical companies including Roche, Barr Laboratories, Mylan, and Merck & Company.

Mr. Maloney has more than 20 years of experience in pharmaceuticals and biologics regulatory affairs. His experience spans numerous therapeutic areas including immunology, oncology, endocrinology, dermatology, neurology, and infectious diseases as well as rare diseases.

He holds a bachelor’s degree in Chemistry from Allegheny College.

Close

Mr. Sananes is the Senior Director of Manufacturing and Validation for ADMA Biologics. In this position, he is responsible for manufacturing and validation operations.

Mr. Sananes has been at the ADMA Biologics manufacturing site since 1998 in various positions including Manufacturing, Validation, and Process Development.

He has more than 30 years of pharmaceutical experience in plasma and vaccine production. Prior to joining ADMA, Mr. Sananes had roles of increasing responsibility at Roche and Wyeth in both Manufacturing and Quality Control.

Mr. Sananes holds bachelor’s and master’s degrees in Biology and Biochemistry from Rutgers University.

Close

Mr. Bloom is the Director of Investor Relations and Corporate Strategy for ADMA Biologics. He serves as a strategic advisor to the senior management team for investor relations and business development opportunities as well as developing messaging for internal and external communications.

Mr. Bloom joined ADMA Biologics in August 2020. Prior to joining ADMA, he held analyst roles at multiple hedge funds including Sphera Global Healthcare and B Group Capital. In his former capacity, Mr. Bloom invested in both private and publicly traded healthcare companies. During his tenure at Sphera, Mr. Bloom played an integral role in growing the investment platform from $500 million assets under management to $1.8 billion at the time of his exit.

He earned his BA in Finance and Accounting from Southern Methodist University.

Close